Importantly, your dose may need to increase as your body adjusts and your weight loss progresses
Part of this was reflective of the fact that work on other intestinal peptides had proven disappointing
Retatrutide is an investigational once-weekly injectable peptide that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved single or dual receptor agonists such as semaglutide and tirzepatide
In summary, whilst the question of whether one can 'stack' retatrutide and tesamorelin may arise in online wellness communities, there is no clinical evidence, regulatory approval, or safety data to support this practice
There are other weight loss tablets available, but they are not GLP-1 medications
These signals suggest your gut has not yet adapted to the current dose level, and adding more stimulation will only make things worse